» Articles » PMID: 37276889

Biodegradable NIR-II Pseudo Conjugate Polymeric Nanoparticles Amplify Photodynamic Immunotherapy Via Alleviation of Tumor Hypoxia and Tumor-Associated Macrophage Reprogramming

Overview
Journal Adv Mater
Date 2023 Jun 5
PMID 37276889
Authors
Affiliations
Soon will be listed here.
Abstract

Photodynamic therapy (PDT) has achieved great success in cancer treatment. Despite its great promise, the efficacy of photodynamic immunotherapy can be limited by the hypoxia in solid tumors which is closely related to the abnormal tumor vasculature. These abnormal vasculatures are a hallmark of most solid tumors and facilitate immune evasion. Therefore, tumor vascular normalization is developed as a promising strategy to overcome tumor hypoxia, resulting in improved cancer therapy. Here, a NIR-II bio-degradable pseudo-conjugate polymer (PSP)-based photodynamic polymer is designed to deliver a vascular normalization agent, i.e., regorafenib (Reg) in nanoparticles (NP-PDT@Reg). NP-PDT@Reg under 808 nm laser irradiation (NP-PDT@Reg + L) can efficiently release Reg to improve the tumor hypoxia via vascular normalization, making more NP-PDT@Reg and oxygen enter the tumors. Moreover, NP-PDT@Reg + L can further result in generation of more reactive oxygen species (ROS) to eradicate tumor cells while inducing immunogenic cell death (ICD) to activate anti-tumor immune responses. In addition, Reg can reprogram TAM from a pro-tumor M2 phenotype to a tumor-killing M1 phenotype as well, thereby reversing the immunosuppressive tumor microenvironment. Taken together, the current study provides an innovative perspective on the development of novel nanomaterials to overcome the limitations in photodynamic immunotherapy.

Citing Articles

Multifunctional nanoparticles and collagenase dual loaded thermosensitive hydrogel system for enhanced tumor-penetration, reversed immune suppression and photodynamic-immunotherapy.

Yang C, Liao X, Zhou K, Yao Y, He X, Zhong W Bioact Mater. 2025; 48:1-17.

PMID: 40028237 PMC: 11870144. DOI: 10.1016/j.bioactmat.2025.02.014.


Copper-based metal-organic frameworks for antitumor application.

Qian Y, Wang C, Xu R, Wang J, Chen Q, Zhu Z J Nanobiotechnology. 2025; 23(1):135.

PMID: 39987136 PMC: 11847370. DOI: 10.1186/s12951-025-03220-5.


Macrophage Polarisation in the Tumour Microenvironment: Recent Research Advances and Therapeutic Potential of Different Macrophage Reprogramming.

Guo R, Wang R, Zhang W, Li Y, Wang Y, Wang H Cancer Control. 2025; 32:10732748251316604.

PMID: 39849988 PMC: 11758544. DOI: 10.1177/10732748251316604.


Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer.

Hu D, Li Y, Li R, Wang M, Zhou K, He C Acta Pharm Sin B. 2025; 14(12):5106-5131.

PMID: 39807318 PMC: 11725102. DOI: 10.1016/j.apsb.2024.10.015.


Recent advances in ferrocene-based nanomedicines for enhanced chemodynamic therapy.

Wu G, Tan S, Tan X, Chen G, Yang Q Theranostics. 2025; 15(2):384-407.

PMID: 39744691 PMC: 11671379. DOI: 10.7150/thno.101697.